Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 85. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Tasadenoturev active in DIPG1218
A new standard of care for advanced-stage urothelial carcinoma888
From little subclones grow mighty oaks826
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma818
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC810
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes786
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC707
Ecological management of the microbiota in patients with cancer698
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime615
Hodgkin lymphoma: great progress with room for improvement609
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care609
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials603
Novel ICI–TKI combination improves HCC outcomes593
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety523
The emerging roles of circRNAs in cancer and oncology512
Current understanding and management of CAR T cell-associated toxicities512
Gut microbiota in colorectal cancer development and therapy459
From ESMO 2022450
From the ESMO Congress 2021442
Mortality is similar with active monitoring423
Contrasting results with second-line CAR T cells in large B cell lymphoma371
Ponatinib superior to imatinib in Ph+ ALL364
Minimal residual disease as a target for liquid biopsy in patients with solid tumours359
Predicting cancer outcomes with radiomics and artificial intelligence in radiology358
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?354
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials334
Understanding and overcoming multidrug resistance in cancer318
Sacituzumab tirumotecan improves OS in mTNBC313
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence281
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC278
Humanized mouse models for immuno-oncology research263
Harnessing cytokines and chemokines for cancer therapy253
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours239
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease238
Craniospinal irradiation improves leptomeningeal metastasis control236
Survival benefit with second-line combination in endometrial cancer235
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer233
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs230
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC230
Spatial landscapes of cancers: insights and opportunities229
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma229
Improving outcomes in patients with oesophageal cancer222
Harnessing big data to characterize immune-related adverse events219
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests219
Biomarkers for immunotherapy of hepatocellular carcinoma208
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship198
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response198
Approvals in 2022: overall survival, dose optimization, new approvals and beyond196
New CAPSTONE of SCLC therapy?187
SHINE a light: frontline ibrutinib for MCL176
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC173
Women with clinically node negative breast cancer can safely avoid axillary surgery171
Prospective comparisons support the use of navigational bronchoscopy168
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond166
Aumolertinib is effective in NSCLC157
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC157
DREAMseq of therapy for BRAF-mutant melanoma154
From ESMO 2023: advances in lung cancer147
Mitigating acute chemotherapy-associated adverse events in patients with cancer147
Targeting chromosomal instability in patients with cancer141
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer139
Circulating tumour DNA — looking beyond the blood136
Long-term outcomes following CAR T cell therapy: what we know so far136
Benefit with ramucirumab in mesothelioma122
Response to neoadjuvant endocrine therapy complements recurrence score119
Multiomics STEP up in correlative analysis of response to CAR T cells118
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress118
From the ESMO Congress 2023112
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM110
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas106
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL105
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma101
Newly approved cancer drugs in China — innovation and clinical benefit96
HAIC-FO improves outcomes in HCC96
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC94
Claudin 18.2 as a novel therapeutic target93
Enhancing immunotherapy with tumour-responsive nanomaterials93
Clinical implications of T cell exhaustion for cancer immunotherapy93
Lung cancer in patients who have never smoked — an emerging disease90
Combining CAR T cells effective in RRMM90
Targeted biopsy reduces detection of clinically insignificant cancer90
Two decades of advances in clinical oncology — lessons learned and future directions90
T-DXd effective as second-line therapy in G/GEJ cancers88
Second-line tarlatamab improves OS in SCLC86
Less-frequent surveillance is noninferior to annual mammography86
0.033250093460083